Abstract
The murine double minute 2 protein (MDM2) and TP53 interact in regulating cell cycle, DNA repair and apoptosis process, which is crucial in carcinogenesis. Since functional variations in these two genes were shown to change gene expression and function, we hypothesized that potentially functional polymorphisms in these genes may contribute to colorectal cancer (CRC) susceptibility. A hospital-based case–control study consisting of 444 patients and 569 controls was conducted to explore the associations between TP53 Arg72Pro and MDM2 T309G and CRC risk in Chinese. The combined effect of TP53 Arg72Pro and MDM2 T309G was significant in a gene dose–response increasing CRC risk (trend test: P = 0.02). Individuals carrying 3 or more potential risk alleles had 1.78 times risk (95 % CI: 1.13–2.80) to develop CRC compared with individuals without potential risk allele. This increased cancer risk was more pronounced in smokers who carried 3–4 potential risk alleles (OR = 2.75, 95 % CI: 1.14–6.60) and in young subjects (OR = 2.05, 95 % CI: 1.08–3.88). The gene–gene interaction between TP53 Arg72Pro and MDM2 T309G may interact in carcinogenesis of CRC in Chinese, especially in smokers, and this kind of interaction is associated with onset age of CRC.
Similar content being viewed by others
References
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917
de la Chapelle A (2004) Genetic predisposition to colorectal cancer. Nat Rev Cancer 4:769–780
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300
Wan DS (2009) Epidemiologic trend of and strategies for colorectal cancer. Ai Zheng 28:897–902
Marte B (2002) Cancer: super p53. Nature 420:279
Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445:661–665
Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S (2009) Suppression of induced pluripotent stem cell generation by the p53–p21 pathway. Nature 460:1132–1135
Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365
Hamajima N, Matsuo K, Suzuki T, Nakamura T, Matsuura A, Hatooka S, Shinoda M, Kodera Y, Yamamura Y, Hirai T, Kato T, Tajima K (2002) No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett 181:81–85
Zhu ZZ, Wang AZ, Jia HR, Jin XX, He XL, Hou LF, Zhu G (2007) Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol 37:385–390
Misra C, Majumder M, Bajaj S, Ghosh S, Roy B, Roychoudhury S (2009) Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. Mol Carcinog 48:790–800
Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, Jarvinen HJ, Mecklin JP, Atula T, Kontio R, Makitie AA, Suominen S, Leivo I, Vahteristo P, Aaltonen LM, Aaltonen LA (2005) The MDM2 promoter polymorphism SNP309T–>G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42:694–698
Levav-Cohen Y, Haupt S, Haupt Y (2005) MDM2 in growth signaling and cancer. Growth Factors 23:183–192
Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591–602
Xu B, Xu Z, Cheng G, Min ZC, Mi Y, Zhang ZZ, Tao J, Li PC, Wang ML, Tang JL, Zhang ZD, Zhang W, Wu HF, Feng NH, Hua LX (2010) Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese. Cancer Genet Cytogenet 202:76–81
Buetow KH, Edmonson M, MacDonald R, Clifford R, Yip P, Kelley J, Little DP, Strausberg R, Koester H, Cantor CR, Braun A (2001) High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci USA 98:581–584
Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307–310
Vousden KH, Lu X (2002) Live or let die: the cell’s response to p53. Nat Rev Cancer 2:594–604
Yap DB, Hsieh JK, Chan FS, Lu X (1999) MDM2: a bridge over the two tumour suppressors, p53 and Rb. Oncogene 18:7681–7689
Moll UM, Petrenko O (2003) The MDM2-p53 interaction. Mol Cancer Res 1:1001–1008
Mo P, Wang H, Lu H, Boyd DD, Yan C (2010) MDM2 mediates ubiquitination and degradation of activating transcription factor 3. J Biol Chem 285:26908–26915
Chen L, Li Z, Zwolinska AK, Smith MA, Cross B, Koomen J, Yuan ZM, Jenuwein T, Marine JC, Wright KL, Chen J (2010) MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output. EMBO J 29:2538–2552
Barak Y, Juven T, Haffner R, Oren M (1993) MDM2 expression is induced by wild type p53 activity. EMBO J 12:461–468
Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80–83
Ouban A, Dellis J, Salup R, Morgan M (2003) Immunohistochemical expression of MDM2 and p53 in penile verrucous carcinoma. Ann Clin Lab Sci 33:101–106
Shiina H, Igawa M, Shigeno K, Yamasaki Y, Urakami S, Yoneda T, Wada Y, Honda S, Nagasaki M (1999) Clinical significance of MDM2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis. Oncology 56:239–247
Shwe M, Chiguchi G, Yamada S, Nakajima T, Maung KK, Takagi M, Amagasa T, Tsuchida N (2001) P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas. J Med Dent Sci 48:113–119
Vazquez A, Bond EE, Levine AJ, Bond GL (2008) The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7:979–987
Venot C, Maratrat M, Dureuil C, Conseiller E, Bracco L, Debussche L (1998) The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J 17:4668–4679
Pim D, Banks L (2004) p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108:196–199
Fang S, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson CD, Bachinski LL, Strong LC, Amos CI (2010) Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One 5:e10813
Wang JJ, Zheng Y, Sun L, Wang L, Yu PB, Dong JH, Zhang L, Xu J, Shi W, Ren YC (2011) TP53 codon 72 polymorphism and colorectal cancer susceptibility: a meta-analysis. Mol Biol Rep 38:4847–4853
Dahabreh IJ, Linardou H, Bouzika P, Varvarigou V, Murray S (2010) TP53 Arg72Pro polymorphism and colorectal cancer risk: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 19:1840–1847
Cao X, Zhang T, Zhao Z, Zhao T (2012) MDM2 SNP309 polymorphism and colorectal cancer risk: a meta-analysis. DNA Cell Biol 31:354–358
Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun T, Zhao D, Yu D, Liu J, Lin D (2007) Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 28:1996–2001
Joshi AM, Budhathoki S, Ohnaka K, Mibu R, Tanaka M, Kakeji Y, Maehara Y, Okamura T, Ikejiri K, Futami K, Maekawa T, Yasunami Y (2011) TP53 R72P and MDM2 SNP309 polymorphisms and colorectal cancer risk: the Fukuoka colorectal cancer study. Jpn J Clin Oncol 41:232–238
Chua HW, Ng D, Choo S, Lum SS, Li H, Soh LY, Sabapathy K, Seow A (2010) Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. BMC Cancer 10:88
Ihsan R, Devi TR, Yadav DS, Mishra AK, Sharma J, Zomawia E, Verma Y, Phukan R, Mahanta J, Kataki AC, Kapur S, Saxena S (2010) Investigation on the role of p53 codon 72 polymorphism and interactions with tobacco, betel quid, and alcohol in susceptibility to cancers in a high-risk population from North East India. DNA Cell Biol 30:163–171
Caceres DD, Quinones LA, Schroeder JC, Gil LD, Irarrazabal CE (2009) Association between p53 codon 72 genetic polymorphism and tobacco use and lung cancer risk. Lung 187:110–115
Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, Wang Y, Lin D (2006) Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 27:110–117
Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA, Levine AJ (2006) MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet 43:950–952
Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, Belluco C, Montagna M, Agata S, D’Andrea E, Nitti D, Amadori A, Bertorelle R (2006) Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 98:285–288
Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, Chompret A, Bressac-de Paillerets B, Stoppa-Lyonnet D, Bonaiti-Pellie C, Frebourg T (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43:531–533
Acknowledgments
This work was supported by the project of the Ministry of Finance and Health of China (2009–193, Jigui Chen, principal investigator), the National Natural Science Foundation of China (NSFC-30972534 and NSFC-81172752, Shaofa Nie, principal investigator). We thank all the patients and controls participated in this study for their cooperation and Chang Liu (Department of Surgery, The Eighth Hospital of Wuhan City) for her effort in collection of clinical samples and epidemiological data.
Conflict of interests
There is no conflict of interests.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Zhang, Y., Liu, L., Tang, Y. et al. Polymorphisms in TP53 and MDM2 contribute to higher risk of colorectal cancer in Chinese population: a hospital-based, case–control study. Mol Biol Rep 39, 9661–9668 (2012). https://doi.org/10.1007/s11033-012-1831-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-012-1831-5